Meniere’s disease is one of the most common inner ear diseases characterized by episodic vertigo, sensorineural hearing loss that fluctuates during episodes, tinnitus, and ear fullness.
Meniere’s Disease market report provides current treatment practices, emerging drugs, Meniere’s Disease (MD) market share of the individual therapies, current and forecasted Meniere’s Disease (MD) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Meniere’s Disease (MD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Meniere’s Disease Market Outlook
There is no cure for Ménière’s disease, so treatment focuses on managing symptoms. Hence ideal treatment aims to stop vertigo attacks, restore hearing, and eliminate tinnitus and ear fullness. Furthermore, all current treatment options are symptomatic with conventional treatments including salt restriction, diuretics and betahistine, intratympanic gentamicin and steroids, ablative surgical therapies endolymphatic sac surgery, and Meniett device.
Salt Restriction is essential as high salt intake can affect the concentration of electrolytes in the blood, which affects the composition of endolymph. The fluctuation in the composition and volume of endolymph contributes to the floating nature of symptoms experienced by people suffering from Meniere’s disease.
Betahistine is a weak histamine H1 receptor agonist and a potent histamine H3 receptor antagonist. It is suggested to improve microvascular circulation in stria vascularis that reduces the endolymph pressure, and it inhibits vestibular nuclei activity that results in longer and more comfortable recovery. Betahistine is a famous agent in Europe and Japan. FDA does not approve its use in vertigo as it is not commonly used in the USA.
Other treatments widely used for Meniere’s disease treatment include diuretics. Thiazide group of diuretics is usually suggested. The cells that produce endolymph, such as dark cells and stria vascularis, contain carbonic anhydrase. Carbonic anhydrase inhibitors like acetazolamide are recommended in order to reduce the production endolymph. Besides these, Intratympanic gentamicin Injection is recommended, basically involving injecting the antibiotic gentamicin into the middle ear to help control vertigo. Gentamicin is an aminoglycoside antibiotic having more vestibulotoxic than cochleotoxic effect. It mainly causes atrophy on type 1 vestibular cells as well as the neuroepithelium. However, some doctors inject a corticosteroid instead, which often helps reduce dizziness and has no risk of hearing loss. It basically reduces the inflammation in the ear and increase labyrinth circulation. Furthermore, Antihistamines, such as dimenhidrate, meclizine, benzodiazepines, and scopolamine, and anti-dopamines, which have antiemetic effects, such as metoclopramide and fenotiazines, are used to suppress the vestibular symptoms. These agents also have sedative effects that could help to reduce the patients’ anxiety. Diazepam is also useful on GABA receptors in the vestibular nucleus and inhibits its response.
Besides these therapies, endolymphatic sac surgery on the endolymphatic sac of the inner ear is also suggested in some cases. A small amount of bone is elimianted from around the endolymphatic sac in order to decrease the pressure of the fluid in the sac.
Also, pulse pressure treatment, introduced by Medtronic involves the use of Meniett device (FDA approved for Meniere’s disease). The device fits into the outer ear and delivers intermittent air pressure pulses to the middle ear. The air pressure pulses appear to act on endolymph fluid to prevent dizziness. For patients with severe hearing loss who do not respond to other surgical and medical treatments, labyrinthectomy is typically the last choice for unilateral MD. The procedure involves the removal of vestibular end organs of five neuroepithelium: the three semicircular canals, the utriculus, and sacculus.
Scope of the Report
- The report covers the descriptive overview of Meniere’s Disease (MD) , explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Meniere’s Disease (MD) epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Meniere’s Disease (MD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Meniere’s Disease (MD) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Meniere’s Disease (MD) market
1. Key Insights
2. Executive Summary of Meniere’s Disease (MD)
3. Competitive Intelligence Analysis for Meniere’s Disease (MD)
4. Meniere’s Disease (MD) : Market Overview at a Glance
4.1. Meniere’s Disease (MD) Total Market Share (%) Distribution in 2017
4.2. Meniere’s Disease (MD) Total Market Share (%) Distribution in 2030
5. Meniere’s Disease (MD) : Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Meniere’s Disease (MD) Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Meniere’s Disease (MD) Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Meniere’s Disease (MD) Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Meniere’s Disease (MD) Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Meniere’s Disease (MD) Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Meniere’s Disease (MD) Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Meniere’s Disease (MD) Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Meniere’s Disease (MD) Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Meniere’s Disease (MD) Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Meniere’s Disease (MD) Treatment and Management
8.2. Meniere’s Disease (MD) Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Meniere’s Disease (MD) Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Meniere’s Disease (MD) : Seven Major Market Analysis
13.1. Key Findings
13.2. Meniere’s Disease (MD) Market Size in 7MM
13.3. Meniere’s Disease (MD) Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Meniere’s Disease (MD) Total Market Size in the United States
15.1.2. Meniere’s Disease (MD) Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Meniere’s Disease (MD) Total Market Size in Germany
15.3.2. Meniere’s Disease (MD) Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Meniere’s Disease (MD) Total Market Size in France
15.4.2. Meniere’s Disease (MD) Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Meniere’s Disease (MD) Total Market Size in Italy
15.5.2. Meniere’s Disease (MD) Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Meniere’s Disease (MD) Total Market Size in Spain
15.6.2. Meniere’s Disease (MD) Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Meniere’s Disease (MD) Total Market Size in the United Kingdom
15.7.2. Meniere’s Disease (MD) Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Meniere’s Disease (MD) Total Market Size in Japan
15.8.3. Meniere’s Disease (MD) Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Meniere’s Disease (MD)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/